Northern Trust Corp boosted its position in Endocyte, Inc. (NASDAQ:ECYT) by 503.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 782,447 shares of the biopharmaceutical company’s stock after buying an additional 652,821 shares during the quarter. Northern Trust Corp owned approximately 1.11% of Endocyte worth $10,797,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently made changes to their positions in ECYT. Wells Fargo & Company MN raised its position in Endocyte by 2,272.7% in the 1st quarter. Wells Fargo & Company MN now owns 33,218 shares of the biopharmaceutical company’s stock valued at $303,000 after buying an additional 31,818 shares during the last quarter. BlackRock Inc. raised its position in Endocyte by 50.2% in the 1st quarter. BlackRock Inc. now owns 1,710,716 shares of the biopharmaceutical company’s stock valued at $15,551,000 after buying an additional 571,925 shares during the last quarter. Guggenheim Capital LLC acquired a new stake in Endocyte in the 1st quarter valued at approximately $145,000. Franklin Street Advisors Inc. NC acquired a new stake in Endocyte in the 2nd quarter valued at approximately $309,000. Finally, Raymond James Financial Services Advisors Inc. acquired a new stake in Endocyte in the 2nd quarter valued at approximately $270,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.
ECYT stock opened at $23.56 on Friday. Endocyte, Inc. has a twelve month low of $2.81 and a twelve month high of $23.89.
Endocyte (NASDAQ:ECYT) last posted its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.01). The company had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.02 million. Endocyte had a negative net margin of 32,296.09% and a negative return on equity of 28.64%. On average, analysts anticipate that Endocyte, Inc. will post -0.65 EPS for the current fiscal year.
In other Endocyte news, insider Philip S. Low sold 5,928 shares of the firm’s stock in a transaction that occurred on Friday, October 5th. The stock was sold at an average price of $15.56, for a total value of $92,239.68. Following the completion of the transaction, the insider now directly owns 325,745 shares in the company, valued at $5,068,592.20. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Katherine Parker sold 6,771 shares of the firm’s stock in a transaction that occurred on Friday, October 5th. The shares were sold at an average price of $15.55, for a total value of $105,289.05. Following the completion of the transaction, the vice president now owns 70,349 shares of the company’s stock, valued at $1,093,926.95. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 66,940 shares of company stock valued at $1,077,041. Corporate insiders own 14.86% of the company’s stock.
A number of equities research analysts recently issued reports on ECYT shares. BidaskClub lowered Endocyte from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 8th. Cowen restated a “buy” rating on shares of Endocyte in a research note on Monday, September 10th. Wells Fargo & Co downgraded Endocyte from an “outperform” rating to a “market perform” rating in a research note on Friday, October 19th. Jefferies Financial Group restated a “buy” rating and issued a $21.00 price target on shares of Endocyte in a research note on Thursday, August 2nd. Finally, Wedbush raised their price target on Endocyte from $15.00 to $21.00 and gave the company an “outperform” rating in a research note on Monday, July 16th. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $20.00.
WARNING: “Northern Trust Corp Purchases 652,821 Shares of Endocyte, Inc. (ECYT)” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.americanbankingnews.com/2018/11/10/northern-trust-corp-purchases-652821-shares-of-endocyte-inc-ecyt.html.
Endocyte, Inc, a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer.
Featured Article: Why investors pay attention to retained earnings
Receive News & Ratings for Endocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte and related companies with MarketBeat.com's FREE daily email newsletter.